Document is current

Article History

Received: 4 August 2025

Accepted: 31 March 2026

First Online: 27 May 2026

Change Date: 13 June 2026

Change Type: Update

Change Details: Duplicated footnote has been removed from Figure 2 in the original publication.

Declarations

:

: Dr Correll reports that he has been a consultant and/or advisor to or has received honoraria from AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Johnson & Johnson, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Response Pharmaceutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Johnson & Johnson, Lundbeck and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Johnson & Johnson and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran. Dr Sanchez reports that he has been a consultant and/or advisor to or has received honoraria from Angelini, Casen-Recordati, Johnson & Johnson, Lundbeck, Osakidetza, Otsuka, Rovi, and University of Deusto. All the other authors are employees of Johnson & Johnson and may hold company stocks or stock options in Johnson & Johnson.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Conception and design: all authors. Acquisition of data: all authors. Data analysis and interpretation: all authors. Manuscript writing and editing: all authors. Final approval of manuscript: all authors. Accountable for all aspects of the work: all authors. All authors met ICMJE criteria and all those who fulfilled those criteria are listed as authors. All authors had access to the study data, provided direction and comments on the manuscript, made the final decision about where to publish these data, and approved submission to the journal.